Manuscript title: Choosing between HLA-Mismatched Unrelated and Haploidentical donors: Donor age considerations

Table 1. EEA and UK exclusion summary. General Data Protection Regulation (GDPR) limits the release of EEA and UK patient-level data publicly

Characteristic	N (%)
No. of patients	61
No. of centers	11
Recipient Age Group - no. (%)	
Median (min-max)	57.6 (6.2-79.3)
<30	8 (13.1)
30-49	14 (23.0)
50+	39 (63.9)
Sex - no. (%)	
Male	38 (62.3)
Female	23 (37.7)
Race - no. (%)	
White	53 (86.9)
Black or African American	4 (6.6)
Asian	3 (4.9)
Not reported	1 (1.6)
Ethnicity - no. (%)	
Hispanic or Latino	1 (1.6)
Non-Hispanic or non-Latino	8 (13.1)
Non-resident of the U.S.	52 (85.2)
Karnofsky score prior to HCT - no. (%)	
90-100%	46 (75.4)
< 90%	13 (21.3)
Not reported	2 (3.3)
HCT-CI - no. (%)	
0	26 (42.6)
1	10 (16.4)
2	5 (8.2)
3	10 (16.4)
4	6 (9.8)
5+	4 (6.6)
Disease - no. (%)	
Acute myelogenous leukemia or ANLL	25 (41.0)

Characteristic	N (%)
Acute lymphoblastic leukemia	10 (16.4)
Chronic myelogenous leukemia	2 (3.3)
Myelodysplastic/myeloprolifterative disorders (please classify all preleukemias)	21 (34.4)
Myeloproliferative Neoplasms	3 (4.9)
AML pre-HCT disease stage - no. (%)	
CR1	18 (29.5)
CR2	5 (8.2)
Advanced or active disease	2 (3.3)
N/A-did not have this disease	36 (59.0)
ALL pre-HCT disease stage - no. (%)	
CR1	4 (6.6)
CR2	5 (8.2)
CR3+	1 (1.6)
N/A-did not have this disease	51 (83.6)
CML pre-HCT disease stage - no. (%)	
Chronic phase	2 (3.3)
N/A-did not have this disease	59 (96.7)
MDS pre-HCT disease stage - no. (%)	
Early	10 (16.4)
Advanced	12 (19.7)
N/A-did not have this disease	37 (60.7)
Not reported	2 (3.3)
Recipient CMV serostatus - no. (%)	
Negative(Non-reactive)	17 (27.9)
Positive(Reactive)	43 (70.5)
Not reported	1 (1.6)
Recipient abotype - no. (%)	
A	14 (23.0)
B	5 (8.2)
AB	2 (3.3)
O	12 (19.7)
Not reported	28 (45.9)
Graft type - no. (%)	
Bone marrow	8 (13.1)
Peripheral blood	53 (86.9)
Conditioning regimen - no. (%)	
TBI/Cy/Flu	10 (16.4)

Characteristic	N (%)
TBI/VP	4 (6.6)
TBI/Flu	2 (3.3)
Bu/Cy	31 (50.8)
Flu/Bu/TT	6 (9.8)
Flu/Bu	3 (4.9)
Flu/Mel/TT	2 (3.3)
Treosulfan	3 (4.9)
Center-reported conditioning intensity - no. (%)	
MAC	36 (59.0)
NST/RIC	25 (41.0)
GVHD prophylaxis - no. (%)	
PtCy + other(s)	61 (100)
Donor/recipient CMV serostatus - no. (%)	
+/+	27 (44.3)
+/-	5 (8.2)
-/+	16 (26.2)
-/-	12 (19.7)
Not reported	1 (1.6)
Donor age at transplant - no. (%)	
Median (min-max)	36.0 (18.8-75.3)
18-29	20 (32.8)
30-49	34 (55.7)
50+	7 (11.5)
Donor/recipient sex match - no. (%)	
M-M	30 (49.2)
M-F	13 (21.3)
F-M	8 (13.1)
F-F	10 (16.4)
Donor race - no. (%)	
White	17 (27.9)
Black or African American	2 (3.3)
Asian	2 (3.3)
More than one race	1 (1.6)
Not reported	39 (63.9)
Donor ethnicity - no. (%)	
Hispanic or Latino	1 (1.6)
Non Hispanic or non-Latino	13 (21.3)
Non-resident of the U.S.	9 (14.8)

Characteristic	N (%)
Not reported	38 (62.3)
X/8 match - no. (%)	
4	43 (70.5)
5	6 (9.8)
7	12 (19.7)
Year of transplant - no. (%)	
2013	1 (1.6)
2014	2 (3.3)
2015	4 (6.6)
2016	7 (11.5)
2017	14 (23.0)
2018	12 (19.7)
2019	12 (19.7)
2020	8 (13.1)
2021	1 (1.6)
Follow-up - median (range)	38.0 (0.0-79.3)